I have a hard time imagining that one or two weeks of 700ml doses are going to have an effect on Cancer, MS, NASH, or other patients. And I doubt blood drawn during this emergency will be tested for anything other than the markers that are necessary to monitor survival probability. I like your idea, but I don't see how this contributes to any clinical evidence.

I do think there might be something to be gleaned from the opposite scenario -- meaning the incidence non-related diseases in patients in leronlimab clinical trials. In other words, the incidence of cancer, NASH, MS, etc in those taking the drug for, say, HIV.